CervoMed (CRVO) Competitors $9.80 +0.31 (+3.27%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$9.85 +0.05 (+0.51%) As of 04/17/2025 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRVO vs. RNAC, CKPT, TECX, PHAT, RGNX, BNTC, ALLO, ORKA, TKNO, and TRDAShould you be buying CervoMed stock or one of its competitors? The main competitors of CervoMed include Cartesian Therapeutics (RNAC), Checkpoint Therapeutics (CKPT), Tectonic Therapeutic (TECX), Phathom Pharmaceuticals (PHAT), REGENXBIO (RGNX), Benitec Biopharma (BNTC), Allogene Therapeutics (ALLO), Oruka Therapeutics (ORKA), Alpha Teknova (TKNO), and Entrada Therapeutics (TRDA). These companies are all part of the "pharmaceutical products" industry. CervoMed vs. Cartesian Therapeutics Checkpoint Therapeutics Tectonic Therapeutic Phathom Pharmaceuticals REGENXBIO Benitec Biopharma Allogene Therapeutics Oruka Therapeutics Alpha Teknova Entrada Therapeutics Cartesian Therapeutics (NASDAQ:RNAC) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, community ranking, media sentiment and dividends. Is RNAC or CRVO more profitable? CervoMed has a net margin of -118.68% compared to Cartesian Therapeutics' net margin of -510.72%. Cartesian Therapeutics' return on equity of 0.00% beat CervoMed's return on equity.Company Net Margins Return on Equity Return on Assets Cartesian Therapeutics-510.72% N/A -6.03% CervoMed -118.68%-44.11%-39.81% Do insiders & institutionals believe in RNAC or CRVO? 86.9% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 25.1% of CervoMed shares are held by institutional investors. 57.9% of Cartesian Therapeutics shares are held by company insiders. Comparatively, 36.3% of CervoMed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more risk and volatility, RNAC or CRVO? Cartesian Therapeutics has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, CervoMed has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. Does the MarketBeat Community prefer RNAC or CRVO? Cartesian Therapeutics received 15 more outperform votes than CervoMed when rated by MarketBeat users. Likewise, 95.00% of users gave Cartesian Therapeutics an outperform vote while only 82.14% of users gave CervoMed an outperform vote. CompanyUnderperformOutperformCartesian TherapeuticsOutperform Votes3895.00% Underperform Votes25.00%CervoMedOutperform Votes2382.14% Underperform Votes517.86% Do analysts rate RNAC or CRVO? Cartesian Therapeutics currently has a consensus price target of $42.14, indicating a potential upside of 301.36%. CervoMed has a consensus price target of $27.50, indicating a potential upside of 180.61%. Given Cartesian Therapeutics' higher probable upside, analysts plainly believe Cartesian Therapeutics is more favorable than CervoMed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cartesian Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.80CervoMed 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.89 Which has better earnings and valuation, RNAC or CRVO? CervoMed has lower revenue, but higher earnings than Cartesian Therapeutics. CervoMed is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCartesian Therapeutics$38.91M6.99-$219.71M-$52.83-0.20CervoMed$7.14M11.95-$2.17M-$2.03-4.83 Does the media refer more to RNAC or CRVO? In the previous week, CervoMed had 3 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 3 mentions for CervoMed and 0 mentions for Cartesian Therapeutics. CervoMed's average media sentiment score of 0.73 beat Cartesian Therapeutics' score of 0.30 indicating that CervoMed is being referred to more favorably in the news media. Company Overall Sentiment Cartesian Therapeutics Neutral CervoMed Positive SummaryCartesian Therapeutics beats CervoMed on 11 of the 19 factors compared between the two stocks. Get CervoMed News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRVO vs. The Competition Export to ExcelMetricCervoMedPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$85.29M$6.44B$5.30B$7.35BDividend YieldN/A3.20%5.45%4.30%P/E Ratio-4.836.8921.8617.81Price / Sales11.95230.51380.6697.70Price / CashN/A65.6738.2634.64Price / Book7.545.936.453.98Net Income-$2.17M$142.99M$3.22B$247.81M1 Month Performance4.59%-13.56%-9.75%-7.92%1 Year Performance-59.17%-8.89%11.50%1.52% CervoMed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRVOCervoMed3.4456 of 5 stars$9.80+3.3%$27.50+180.6%-61.2%$85.29M$7.14M-4.834Short Interest ↓Gap UpRNACCartesian Therapeutics1.704 of 5 stars$13.00+21.8%$42.14+224.2%-39.2%$336.79M$38.91M-0.2564CKPTCheckpoint Therapeutics1.6187 of 5 stars$4.01+0.5%$4.33+8.1%+152.5%$335.89M$41,000.00-2.1810TECXTectonic Therapeutic2.6709 of 5 stars$17.87+10.6%$77.75+335.1%N/A$333.51MN/A-3.03120Short Interest ↑Positive NewsGap UpPHATPhathom Pharmaceuticals3.5642 of 5 stars$4.63-5.1%$22.17+378.8%-57.5%$322.42M$55.25M-0.81110Analyst ForecastNews CoverageRGNXREGENXBIO4.6805 of 5 stars$6.33+7.5%$31.88+403.6%-63.1%$317.24M$83.33M-1.26370Analyst ForecastAnalyst RevisionNews CoveragePositive NewsBNTCBenitec Biopharma2.2261 of 5 stars$13.27+5.1%$24.71+86.2%+101.6%$311.20M$80,000.00-8.7920Short Interest ↑ALLOAllogene Therapeutics3.0387 of 5 stars$1.43-1.4%$9.29+549.6%-58.1%$310.69M$22,000.00-0.92310News CoverageORKAOruka Therapeutics3.0786 of 5 stars$8.14+6.0%$39.86+389.6%N/A$304.77MN/A-1.30N/AUpcoming EarningsNews CoverageTKNOAlpha Teknova1.502 of 5 stars$5.67+1.4%$8.50+49.9%+186.6%$302.99M$37.75M-7.66240TRDAEntrada Therapeutics2.978 of 5 stars$7.92+0.3%$25.67+224.1%-31.7%$297.75M$210.78M4.98110Positive News Related Companies and Tools Related Companies RNAC Alternatives CKPT Alternatives TECX Alternatives PHAT Alternatives RGNX Alternatives BNTC Alternatives ALLO Alternatives ORKA Alternatives TKNO Alternatives TRDA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRVO) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CervoMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CervoMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
